Paul Schellhammer

Publications (2)58.02 Total impact

• Article: Sipuleucel-T.

  Celestia S Higano, Eric J Small, Paul Schellhammer, Uma Yasothan, Steven Gubernick, Peter Kirkpatrick, Philip W Kantoff
  dressNature Reviews Drug Discovery 07/2010; 9(7):513-4. · 29.01 Impact Factor
• Article: Fresh from the Pipeline: Sipuleucel-T

  Celestia S. Higano, Eric J. Small, Paul Schellhammer, Uma Yasothan, Steven Gubernick, Peter Kirkpatrick, Philip W. Kantoff
  [show abstract] [hide abstract]
  ABSTRACT: In April 2010, sipuleucel-T (Provenge; Dendreon), an autologous cellular immunotherapy, was approved by the US FDA for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. It is the first therapeutic cancer vaccine to receive FDA approval.
  dressNature Reviews Drug Discovery 06/2010; 9(7):513-514. · 29.01 Impact Factor